HBV Treatment
AASLD 2013: Entecavir + Tenofovir Works Well for Hepatitis B Patients with Prior Treatment Failure
- Details
- Category: HBV Treatment
- Published on Monday, 11 November 2013 00:00
- Written by Liz Highleyman
A dual regimen of entecavir (Baraclude) plus tenofovir (Viread) for 48 weeks led to virological response and was generally well-tolerated as second-line therapy for chronic hepatitis B patients who had failed previous nucleoside/nucleotide treatment, according to a poster presentation at the 64th AASLD Liver Meeting last week in Washington, DC.
AASLD 2013: Hepatitis B Treatment with Entecavir or Tenofovir Lowers, But Does Not Eliminate, HCC Risk
- Details
- Category: HBV Treatment
- Published on Wednesday, 06 November 2013 00:00
- Written by Liz Highleyman
Long-term treatment with entecavir can reduce the likelihood that people with chronic hepatitis B virus (HBV) infection will develop hepatocellular carcinoma, according to findings presented this week at the 64thAASLD Liver Meeting in Washington, DC. Another study, however, found that while entecavir or tenofovir can reduce the risk, people with hepatitis B should continue to undergo regular monitoring for liver cancer, and better predictive models may be needed for Caucasian patients.
IDWeek 2013: Entecavir and Tenofovir Both Work Well Against Hepatitis B in Clinical Practice
- Details
- Category: HBV Treatment
- Published on Tuesday, 15 October 2013 00:00
- Written by Liz Highleyman
Entecavir (Baraclude) and tenofovir (Viread) both demonstrated potent activity against hepatitis B virus (HBV) in a Turkish study presented at the second IDWeek conference held recently in San Francisco. Entecavir appeared to have an edge with regard to hepatitis B "e" antigen (HBeAg) seroconversion, but this rose with time among people taking either drug.
Coverage of the 2013 AASLD Liver Meeting
- Details
- Category: HBV Treatment
- Published on Wednesday, 30 October 2013 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2013) in Washington, DC, November 1-5, 2013.
Conference highlights include treatment for hepatitis B and C, new direct-acting HCV drugs, interferon-free hepatitis C therapy, management of liver disease complications, HIV/HBV and HIV/HCV coinfection, and prevention and treatment of hepatocellular carcioma.
10/30/13
Hepatitis B Treatment with Entecavir Lowers Risk of Liver Cancer
- Details
- Category: HBV Treatment
- Published on Thursday, 01 August 2013 00:00
- Written by Liz Highleyman
Long-term treatment with entecavir (Baraclude) significantly reduces the chances of developing hepatocellular carcinoma compared with no treatment, and appears to lower the risk more than an older drug, especially for the most at-risk patients, according to a report in the July 2013 issue of Hepatology.
Web Design and Development by